Mineralys Therapeutics, Inc. (MLYS) Misses Q3 EPS by 42c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q3 EPS of ($1.13), $0.42 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Needham Starts Red Violet (RDVT) at Buy, 'offers the leading Cloud identity intelligence platform in the market today'
• Getty Realty (GTY) Reiterated at Market Outperform by Citizens Amid Favourable Trends
• Scotiabank Starts Perpetua Resources (PPTA) at Sector Outperform